Compare LEN & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEN | ONC |
|---|---|---|
| Founded | 1954 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0B | 31.4B |
| IPO Year | N/A | N/A |
| Metric | LEN | ONC |
|---|---|---|
| Price | $89.07 | $309.60 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $97.77 | ★ $374.75 |
| AVG Volume (30 Days) | ★ 3.6M | 187.3K |
| Earning Date | 03-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $747.23 |
| Revenue Next Year | $4.41 | $15.78 |
| P/E Ratio | ★ $15.20 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $83.03 | $227.40 |
| 52 Week High | $144.24 | $385.22 |
| Indicator | LEN | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 54.97 |
| Support Level | $83.03 | $307.93 |
| Resistance Level | $124.94 | $320.35 |
| Average True Range (ATR) | 3.37 | 7.68 |
| MACD | 0.73 | 4.77 |
| Stochastic Oscillator | 51.23 | 82.89 |
Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.